explore -WSS

explore

author：fashion 2025-09-29 20:52:42 - browse：977

A pile of Zynex Medical batteries and electrode pads are seen at Michelle Bean's home — A pile of Zynex Medical batteries and electrode pads Kayana Szymczak for STAT

Sending patients heaps of medical supplies to score more money from insurers is common in the device industry. If insurers decline to cover the supplies, patients are stuck paying for materials they didn’t need.

STAT examined one of the companies perpetuating this practice, a pain management device company called Zynex Medical, and the frustration among both its patients and former employees. Here are five takeaways.

The ‘razor blade’ business model

Zynex sells nerve and muscle stimulation machines, known as TENS and EMS units, to treat pain and soothe muscles. But the company makes most of its money from monthly shipments of batteries and electrodes — almost 70% of its $184 million revenue in 2023 came from these supplies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： People can get long Covid without testing positive for virus: Study

knowledge

WSS

Fetal cell organoids grown from amniotic fluid, study finds

PBMs are inflating the cost of generic drugs. They must be reined in

Florida health officials providing scant details on measles cases

Immune cells and nerve overgrowth may explain recurring UTI pain

$1 billion proposal to grow Boston, Massachusetts biotech

Streamlined flu vaccines recommended by FDA advisory panel

Wikipedia

explore

The ‘razor blade’ business model

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Fetal cell organoids grown from amniotic fluid, study finds

Moonlake's readout produced a cash windfall. Risks remain

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Alkermes shareholders re

Kellogg’s is going to war over Mexico’s nutrition label rules

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A new approach to psychiatric drug development

Virginia high school admissions case could be legal follow

Pregnant women don't need prenatal multivitamins, study concludes

hotspot

Republicans love RFK Jr. What's that tell us about health in 2024?

Republicans love RFK Jr. What's that tell us about health in 2024?

PBMs are inflating the cost of generic drugs. They must be reined in

Meadows told special counsel he could not recall Trump ever declassifying Mar

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Stem cell biologist probes earliest stages of human development

hotspot

entertainment

knowledge

focus